Prevalence of High-Burden Medical Conditions Among Young and Middle-Aged Adults With Pediatric-Onset Medical Conditions: Findings From US Private and Public Administrative Claims Data

Document Type: Short Communication

Author

Department of Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, MI, USA

Abstract

Adults with pediatric-onset medical conditions (POMCs) are susceptible to early development of high-burden medical conditions. However, research pertaining to this topic is lacking, which is vital information that could assist in health benefit planning and administration. The purpose of this study was to determine the prevalence of high-burden medical conditions among privately and publicly insured adults with POMCs, as compared to adults without POMCs, from the US. Data from 2016 were extracted from Optum Clinformatics® Data Mart (private insurance) and a random 20% sample from Medicare fee-for-service (public insurance). International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes were used to identify 18–64-year-old beneficiaries with POMCs, as well as several high-burden medical conditions, including pain, fracture, mood affective disorders, anxiety disorders, ischemic heart diseases, cerebrovascular diseases, hypertensive and other cardiovascular diseases, type 2 diabetes, osteoporosis, osteoarthritis, chronic obstructive pulmonary diseases, liver diseases, and cancer. Privately and publicly insured adults with POMCs had higher prevalence of all medical conditions compared to adults without POMCs. Publicly insured adults with POMCs had higher prevalence of all medical conditions compared to privately insured adults with POMCs, except for the lower prevalence of pain and cancer. When stratified by the category of POMCs (eg, musculoskeletal, circulatory), privately and publicly insured groups tended to have higher prevalence of most (private) or all (public) medical conditions compared to adults without POMCs. Adults with POMCs have higher prevalence of several high-burden medical conditions compared to adults without POMCs. This health disparity was present regardless of insurance coverage, but was generally more pronounced for public vs. private insured adults with POMCs.

Highlights

Supplementary File 1 (Download)

Keywords

Main Subjects


  1. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1859-1922. doi:10.1016/S0140-6736(18)32335-3
  2. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1151-1210. doi:10.1016/S0140-6736(17)32152-9
  3. WHO. Global action plan for the prevention and control of noncommunicable diseases 2013-2020. Geneva, Switzerland: World Health Organization;2013.
  4. Global Research on Developmental Disabilities C. Developmental disabilities among children younger than 5 years in 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Glob Health. 2018. doi:10.1016/S2214-109X(18)30309-7
  5. Whitney DG, Hurvitz EA, Ryan JM, et al. Noncommunicable disease and multimorbidity in young adults with cerebral palsy. Clin Epidemiol. 2018;10:511-519. doi:10.2147/CLEP.S159405
  6. Whitney DG, Shapiro DN, Warschausky SA, Hurvitz EA, Peterson MD. The contribution of neurologic disorders to the national prevalence of depression and anxiety problems among children and adolescents. Ann Epidemiol. 2018. doi:10.1016/j.annepidem.2018.11.003
  7. Ryan JM, Allen E, Gormley J, Hurvitz EA, Peterson MD. The risk, burden, and management of non-communicable diseases in cerebral palsy: a scoping review. Dev Med Child Neurol. 2018;60(8):753-764. doi:10.1111/dmcn.13737
  8. Charlson FJ, Baxter AJ, Dua T, Degenhardt L, Whiteford HA, Vos T. Mental, Neurological, and Substance Use Disorders: Disease Control Priorities, Third Edition. Chapter 3 Excess Mortality from Mental, Neurological, and Substance Use Disorders in the Global Burden of Disease Study 2010. Vol 4. Washington DC: The World Bank; 2016.
  9. Reeves S, Garcia E, Kleyn M, et al. Identifying sickle cell disease cases using administrative claims. Acad Pediatr. 2014;14(5 Suppl):S61-67. doi:10.1016/j.acap.2014.02.008
  10. Quinones AR, Markwardt S, Botoseneanu A. Multimorbidity Combinations and Disability in Older Adults. J Gerontol A Biol Sci Med Sci. 2016;71(6):823-830. doi:10.1093/gerona/glw035
  11. Whitney DG, Hurvitz EA, Devlin MJ, et al. Age trajectories of musculoskeletal morbidities in adults with cerebral palsy. Bone. 2018;114:285-291. doi:10.1016/j.bone.2018.07.002
  12. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22(3):465-475. doi:10.1359/jbmr.061113
  13. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2197-2223. doi:10.1016/S0140-6736(12)61689-4
  14. Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382(9904):1575-1586. doi:10.1016/S0140-6736(13)61611-6
  15. Global, regional, and national incidence, prevalence, and years lived with disabilitity for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-1858.
  16. Whitney DG, Alford AI, Devlin MJ, Caird MS, Hurvitz EA, Peterson MD. Adults with cerebral palsy have higher prevalence of fracture compared to adults without cerebral palsy independent of osteoporosis and cardiometabolic diseases. J Bone Miner Res. 2019. doi:10.1002/jbmr.3694
  17. Raghupathi W, Raghupathi V. An Empirical Study of Chronic Diseases in the United States: A Visual Analytics Approach. Int J Environ Res Public Health. 2018;15(3). doi:10.3390/ijerph15030431
  18. Kerr EA, McGlynn EA, Van Vorst KA, Wickstrom SL. Measuring antidepressant prescribing practice in a health care system using administrative data: implications for quality measurement and improvement. Jt Comm J Qual Improv. 2000;26(4):203-216.
  19. Leslie WD, Lix LM, Yogendran MS. Validation of a case definition for osteoporosis disease surveillance. Osteoporos Int. 2011;22(1):37-46. doi:10.1007/s00198-010-1225-2
  20. Doktorchik C, Patten S, Eastwood C, et al. Validation of a case definition for depression in administrative data against primary chart data as a reference standard. BMC Psychiatry. 2019;19(1):9. doi:10.1186/s12888-018-1990-6
  21. Noyes K, Liu H, Lyness JM, Friedman B. Medicare beneficiaries with depression: comparing diagnoses in claims data with the results of screening. Psychiatr Serv. 2011;62(10):1159-1166. doi:10.1176/ps.62.10.pss6210_1159